Background: The disease is caused by the thrombogenesis resulting from the rupture of a coronary atherosclerosis plaque.
As some researchers believe the main cause of the coronary atherosclerosis plaque rupture is the connection of oxLDL autoantigen contained in the atheroma plaques with the anti-oxLDL autoantibody, thus forming an immune complex that activates the immune complement, immune reaction and cell-mediated immune response. Our study proposes that the detection of the above mentioned autoantibody has a significant role in monitoring plaque rupture, prevention of ACS and the treatment control, complication and evaluation of the prognosis.
Aims: To determine the serum level of anti-oxLDL autoantibody and to investigate the role of the above mentioned autoantibody in the prevention of ACS.
Methods: Our research was conducted using the case-control study method. The case group consists of patients with severe coronary stenosis as diagnosed by cardiac angiography (stenosis >85%), the control group- healthy people with carotid artery stenosis (<0.7mm). We measured Anti-oxLDL using ELISA Kit and oxLDL titer by ELISA Kit reagents in the enzyme binding reaction. Total antioxidant capacity (TAC) was determined by using spectrophotometer method.
Results: Anti-oxLDL autoantibodies titer level for case group was (694±30.91 MU/MΠ), which is (627±14.11 MU/MΠ) greater than the control group. It was statistically significant result (p<0.01).
According to the Binary Logistic Regression test, the anti-oxLDL level significantly influenced ACS (OR=1.008, p<0.05). This shows that 1 mU/ml increase of anti-oxLDL autoantibody titer results in 1.008 times or 0.8% increase in the susceptibility of ACS. The significance of determining the above mentioned autoantibody level in treatment and prevention of ACS could be seen from the results of ROC curve test (significant and sensitive area >0.5, p<0.05).
Anti-oxLDL autoantibody titer level had a direct relation with the oxLDL level (r=0.92, p<0.01), and an indirect relation with the TAC level (r=-0.337, p<0.01).
The factors influencing the anti-oxLDL autoantibody level of the case group has been indicated and analyzed using linear regressive test, the results of which showed that cholesterol level (β=2.546, p<0.05), (β=1.149, p<0.005) and oxLDL (β=3.115, p<0.005) are associated with an increase in the autoantibody levels. However, TAC (β=-2.724, p<0.01) level had an indirect relation with the increase.
Conclusions: Anti-oxLDL autoantibodies could be potential and novel biomarkers for the prevention of ACS.